In its 2026 half-year financial report, Ottobock announced it had refined its forecast for the financial year toward an organic core revenue growth of 6-8 percent (previously 5-8 percent) and the adjusted core earnings before interest, taxes, depreciation, and amortization (EBITDA) margin to more than 27 percent (previously more than 26.5 percent).
The highlights of the report included the following:
- Core revenues increased by 7.7 percent to EUR 818.5 million with organic core revenue growth of 6.7 percent.
- Underlying core EBITDA grew by 18.1 percent to EUR 207.0 million; core EBITDA margin reached 25.3 percent.
- There was strategic investment in future human-machine interface technology through Blue Arbor Technologies.
- Ottobock expanded its functional electrical stimulation product portfolio through acquisition of Fesia Technology.
- The company expanded its global patient care network in Norway.
- The company streamlined its portfolio, including sale of the human mobility wheelchair business.
“We delivered a successful first half of the year, in which we outperformed the market thanks to strong organic growth,” said Oliver Jakobi, CEO. “We also focused on expanding our user groups through targeted investments and acquisitions, thereby further strengthening our leading market position.”
To read the half-year report, visit the Ottobock website.
